Sobi, Apellis positive topline in phase 3 kidney disease trial

 

• Met the primary endpoint, achieving statistically significant 68% (p<0.0001) reduction in proteinuria compared to placebo in a broad study population
• Positive results consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, and native and post-transplant kidneys
• Demonstrated favourable safety, consistent with established profile
• Companies plan to submit data for regulatory approval in the US and EU

https://www.prnewswire.co.uk/news-releases/sobi-and-apellis-announce-positive-topline-results-from-phase-3-valiant-study-of-pegcetacoplan-in-c3g-and-primary-ic-mpgn-302217847.html